Regent Investment Management Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Regent Investment Management reduced its stake in Celgene Corporation by 0.59% during the most recent quarter end. The investment management company now holds a total of 41,559 shares of Celgene Corporation which is valued at $4,593,101 after selling 245 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Celgene Corporation makes up approximately 2.51% of Regent Investment Management’s portfolio.

Celgene Corporation opened for trading at $110.34 and hit $111.5 on the upside on Friday, eventually ending the session at $110.52, with a gain of 0.55% or 0.6 points. The heightened volatility saw the trading volume jump to 48,55,538 shares. Company has a market cap of $86,390 M.

Other Hedge Funds, Including , Yhb Investment Advisors reduced its stake in CELG by selling 6,310 shares or 8.18% in the most recent quarter. The Hedge Fund company now holds 70,792 shares of CELG which is valued at $7,823,932. Celgene Corporation makes up approx 2.07% of Yhb Investment Advisors’s portfolio.Gateway Investment Advisers reduced its stake in CELG by selling 55,445 shares or 8.39% in the most recent quarter. The Hedge Fund company now holds 605,718 shares of CELG which is valued at $66,943,953. Celgene Corporation makes up approx 0.57% of Gateway Investment Advisers’s portfolio.Bremer Trust National Association reduced its stake in CELG by selling 823 shares or 1.67% in the most recent quarter. The Hedge Fund company now holds 48,415 shares of CELG which is valued at $5,196,866. Celgene Corporation makes up approx 1.48% of Bremer Trust National Association’s portfolio.First American Bank reduced its stake in CELG by selling 50,323 shares or 46.31% in the most recent quarter. The Hedge Fund company now holds 58,348 shares of CELG which is valued at $6,057,106. Celgene Corporation makes up approx 0.63% of First American Bank’s portfolio.

On the company’s financial health, Celgene Corporation reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.